Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diacerein 1% ointment for generalized epidermolysis bullosa simplex
MOH_2024-07-17_013323Phase 3Recruiting
- Sponsor
- TWi Biotechnology, Inc.
- Start
- Mar 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of diacerein in epidermolysis bullosa simplex (EBS) (2 arms), sponsored by TWi Biotechnology, Inc. Started Mar 2024; status: recruiting.
02
Drugs
diacerein
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on MOH_2024-07-17_013323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-07-17_013323.